维普中文期刊产品整合服务
14篇 您的检索式:作者名="Jan TR"
    题名 作者 年代 出处 被引量
1Role of human epidermal growth factor receptor 2 in gastric cancer:Biological and pharmacological aspects显示文摘Amplification of the human epidermal growth factor receptor 2(HER2)gene and overexpression of the HER2protein is found in 15%-20%of patients with gastric and gastroesophageal junction cancer.The degree of HER2 overexpression and amplification varies with the location of the carcinoma,with higher expression in the gastroesophageal and proximal parts compared to the distal parts of the stomach.Further,HER2 overexpression and amplification also seems to be related to the Lauren histological classification,with higher levels found in the intestinal phenotype compared to the diffuse and mixed types.The prognostic properties of HER2 overexpression and amplification are still under debate,but a large number of studies seem to indicate that HER2 is a negative prognostic factor.The usefulness of HER2 targeted therapy in gastric cancer was demonstrated in the ToGA trial,where HER2-positive patients with advanced gastric and gastroesophageal junction adenocarcinoma were randomized to receive5-FU/capecitabine and cisplatin,either alone or in combination with trastuzumab.A statically significant gain in overall survival was seen in patients who received the combined treatment of trastuzumab and chemotherapy.Patients with a strong overexpression of the HER2 protein(IHC3+)specifically benefited from the treatment,with a median overall survival of 17.9 mo.As a consequence of the positive results of the ToGA trial,patients with advanced gastric or gastroesophageal junction adenocarcinoma are now routinely tested for HER2.The ToGA trial must be characterized as a landmark in the treatment of gastric cancer and it has paved the way for a number of new HER2 targeted compounds such as pertuzumab,ado-trastuzumab emtansine,lapatinib,afatinib,and dacomitinib,which are currently undergoing phaseⅡandⅢclinical testing.Overall,this review will discuss the current status of HER2 in gastric and gastroesophageal junction cancer and the future direction in relation to HER2 target therapy.Jan Tr?st J?rgensen 2014World Journal of Gastroenterology2014,20,16:11
2Diosgenin attenuates allergen - induced intestinal inflammation and IgE production in a murine model of food al- lergy 显示文摘Huang CH Ku CY Jan TR 2009Planta Med2009,75,12:1
3Diosgenin attenuates allergen-induced intesti- nal inflammation and IgE production in a murine model of food allergy 显示文摘Huang CH Ku CY Jan TR 2009Planta Med2009,75,12:1
4CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group显示文摘Michael Pfreundschuh Lorenz Trümper Anders ?sterborg Ruth Pettengell Marek Trneny Kevin Imrie David Ma Devinder Gill Jan Walewski Pier-Luigi Zinzani Rolf Stahel Stein Kvaloy Ofer Shpilberg Ulrich Jaeger Mads Hansen Tuula Lehtinen Armando López-Guillermo C 2006Lancet Oncology2006,,5:1
5Diosgenin attenuates allerg- en-induced intestina 1 inflammation and IgE production in a murine model of food allergy显示文摘Huang CH Ku CY Jan TR 2009Planta Med2009,75,12:1
6CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group显示文摘Michael Pfreundschuh Evelyn Kuhnt Lorenz Trümper Anders ?sterborg Marek Trneny Lois Shepherd Devinder S Gill Jan Walewski Ruth Pettengell Ulrich Jaeger Pier-Luigi Zinzani Ofer Shpilberg Stein Kvaloy Peter de Nully Brown Rolf Stahel Noel Milpied Armando 2011Lancet Oncology2011,,11:1
7Mitochondrial ribosomal RNA mutation associated with both antibiotic2induced and non syndromic deafness 显示文摘Prezant TR Agap Jan JV Bohlman MC 1993Nat Genet1993,4,:1
8Diosgenin attenuates allergen-in- duced intestinal inflammation and IgE production in a murine model of food allergy 显示文摘Huang CH Ku CY Jan TR 2009Planta Med2009,75,12:1
9Inhibitory effect of curcu- min, an anti-inflammatory agent, on vascular smooth mus- cle cell proliferation显示文摘Huang HC Jan TR Yeh SF 1992Eur J Pharmacol1992,221,23:1
10Balloon Dilatation of Pediatric Subglottic Laryngeal Stenosis during the Artificial Apneic Pause: Experience in 5 Children显示文摘J. Lisy D. Groh M. Chovanec M. Marková V. Suchánek P. Polá?ková M. Trávní?ek Jan Plzak 2014BioMed Research International2014,,:1
11CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group显示文摘Michael Pfreundschuh Evelyn Kuhnt Lorenz Trümper Anders ?sterborg Marek Trneny Lois Shepherd Devinder S Gill Jan Walewski Ruth Pettengell Ulrich Jaeger Pier-Luigi Zinzani Ofer Shpilberg Stein Kvaloy Peter de Nully Brown Rolf Stahel Noel Milpied Armando 2011Lancet Oncology2011,,11:1
12Cannabinol enhancement of interleukin-2(IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity显示文摘Jan TR Rao GK Kaminski NE 2002Mol Pharmacol2002,61,2:1
13Inhibitory effect of curcumin, an anti-inflammatory agent,on vascular smooth muscle cell proliferation显示文摘Huang HC Jan TR Yeh SF 1992Eur J Pharmacol1992,221,23:1
14詹姆斯·林德图书馆:解释和说明医学治疗公平试验的发展显示文摘建立詹姆斯·林德图书馆(www.jameslindlibrary.org)的目的是促进公众和专业人员对卫生保健治疗措施的公平试验及其历史的了解。爱丁堡英国皇家内科医生协会在十年前就为其成立奠定了基础,其行政中心位于协会的Sibbald图书馆——全世界收录历史性的医学手稿、文件和书籍的最重要的图书馆之一。詹姆斯·林德图书馆通过系列性含插图的短文(目前有英语、阿拉伯语、中文、法语、葡萄牙语、俄语和西班牙语等版本)向网站登录者介绍治疗措施的公平试验的原则。登陆者可以从网站免费下载《验证治疗措施的公平——高质量研究促进高质量卫生保健》一书(100页)的英语、阿拉伯语和西班牙语版本。为了说明从公元前2000年至今治疗措施的公平试验观念的演变,詹姆斯·林德图书馆收录了手稿、书籍及期刊论文的重要章节和图像,其中很多都附有评注、传记、肖像和其他相关文献、图像,包括音频和视频文件。随着新的相关记录被确认及治疗措施的公平试验方法的进展,网站一直不断地在补充新的材料。当前网站每月有上百万的登陆者,由一个多语种的国际化编辑团队负责及监管其发展。Iain Chalmers Iain Milne Ulrich Trhler Jan Vandenbroucke Alfredo Morabia George Tait Estela Dukan 于洁 王琪 2011中国循证医学杂志2011,11,2:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费